Olumiant® (baricitinib) – New drug approval
June 1, 2018 - Eli Lilly and Incyte announced the FDA approval of Olumiant (baricitinib), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Top